HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55

Benzinga · 2d ago
HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.